Literature DB >> 19195847

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

J M Olivares1, A Rodriguez-Morales, J Diels, M Povey, A Jacobs, Z Zhao, A Lam, J C Villalobos Vega, J Alonso Cuéllar, F J Alberca de Castro, C Morillo-Velarde Quintero, J F Román Martíin, P Tabares Domínguez, J L Prados Ojeda, S Sanz Cortés, F I Mata Cala, C Gutiérrez Marín, L Moyano Castro, M A Haza Duaso, J Requena Albarracín, G Narbona Vergara, A Fernández Benítez, F Mayoral Cleries, J M García-Herrera Pérez-Brian, A Bordallo Aragón, J C Rodríguez Navarro, J A Algarra Biedma, R Bravo de Pedro, J F Delgado González, M E Jaén López, H Díaz Moreno, J A Soto López, E Ojeda Rodríguez, C Martínez de Hoyos, M Pardilla Sacristán, M D Molina Martín, E Martín Ballesteros, P A Sopelana Rodríguez, L Fernández Menéndez, R Santos Rivas, P del Pino Cuadrado, J Correas Lauffer, J J Rodríguez Solano, J M Fernández Martínez, F García Solano, P García-Lamberde Rodríguez, J A Romero Rodríguez, T Rodríguez Cano, M Ducaju Fortacin, J M Blanco Lobeiras, J M Piñeiro Sampedro, A Pérez Bravo, A Fernández Pellicer, M D Alonso López, J Fraga Liste, M Riobo Fernández, A Casas Losada, R Vazquez-Noguerol Mendez, S Agra Romero, J J Blanco Blanco, I Tortajada Bonaselt, M C García Mahia, E Ferrer Gómez del Valle, P Quiroga Yañez, M Gelabert Camarasa, J A Barbado Alonso, G Florez Mendez, F Doce Feliz, M A López Lamela, M Vega Piñero, P Fuentes Alvarado, I López Gómez, P Fadon Martín, J L Santos Gómez, A García López, A Rodríguez Jiménez, A Escudero Nafs, N Casas Barquero, R Fernández-Villamor Ortiz, J L Velez Noguera, P Ruiz Carrasco, J Martín Muñoz, M Masegoza Palma, C Marín Hortelano, L Sánchez Bonome, J Sánchez Sevilla, J M Mongil San Juan, J M García Ramos, J L Vallejo Muñoz, J Elorza Guisasola, L Santamaria Vazquez, F Campo Guerras, F J Arrufat Nebot, F J Baron Fernández, A L Palomo Nicolau, R Catala Subirats, M Messays Kidias, V Fabregat Navarro, B Frades García, F Mejias del Rosal, T de Vicente Muñoz, J Año Ballester, P Malabia Lieb, A Delgado Martel, E Roca Bea, I Grau Joaquim, F Boatas Enjuanes, M Bañuelos Piñol, E Fontova I Carbonell, R Martín Muñoz, C Argila Giribets, L Albages Sans, A Serrano Blanco, M Arcega Felipe, P González Muñoz, A Pons Villanueva, M Bernardo Arroyo, R Coronas Borri, S Miret Fallada, M Celma Merola, E Parellada Rodon, J R Pigem Palmes, E Pérez Martínez, J Matarredona Catala, A Sandoval Coca, F Pascual Ferrandiz, E Ferrandiz Paya, G Iturri Caballero, A Franco Bonet, J Fluvia Figueras, P Moreno Pagador, M Medina Garibo, V Pérez Camo, C Sanz Carrillo, C Pelegrin Valero, F J Caro Rebollo, J García Campayo, J M Sala Sala Ayma, M Martínez Roig, M A de Uña Mateos, R García Bertolin, A Martín García, F Jiménez Mazo, J L Galvez Velasco, L Santa Maria Pérez, C Jiménez Casado, J J Mancheño Barba, M Conde Diaz, J P Alcon Rubio, A Soler Mandoli, A Uson Herrero, A Rodríguez Martínez, P Salgado Serrano, E Nieto Rodríguez, J Segui Montesinos, J Ferragud Macia, A Mateos Mateos Marcos, J V Pérez-Fuster Soto, M Verdaguer Dumont, J Parra Pagan, V Balanza Martínez, M Santiuste de Pablos, C Espinosa Delgado, M D Martínez Quiles, F J Manzanera López, P Pozo Navarro, A Micol Torres, F J Martínez Ingles, J M Salmeron Arias-Camison, J C López Manzano, R Villanueva Peña, G Petersen Guitarte, H Blasco Fontecilla, J Barjau Romero, R Sanz Gil, J Marín Lozano, L Donaire Adanez, I Zarranz Herrera-Oria, J Pérez Jiménez, F Carrato Vaz, O Sanz García, C Contreras Anton, R Reixach Casula, M C Natividad Hernandez, F Teba Escabias, J Rodríguez Torresano, A Huidobro Pérez-Villamil, L Estevez, M Aragües Figuero, A Muñoz de Morales, J L Rodríguez Calvin, M Delgado Criado, V Molina Rodríguez, E Balbo Ambrosolio, P M Holgado Madera, G Ponce Alfaro, M M Rojas Vidal, A García Valtuille, O Ruiz, G Lucas Cabornero, M Echevarria Martínez de Bujo, M J Maicas Mallen, J Santandreu Puigros, A Liñana Martorell, A Clar Forteza, E Rodríguez Arrebola, M Rodríguez de la Torre, C G Anton Saiz, C Bardolet I Casas, E Rodríguez Linde, R De Arce Cordon, E M Padial Molina, F J Ruiz Carazo, J J Muro Romero, D Vico Cano, M Soria Dorado, S Campos Velazquez, A J Rodríguez Sánchez, S Ocio Leon, K Pachas Sánchez, M Henry Benitez, A Intxausti Zugarramurai, M A Contreras, M De la Varga González, P Barreiro Marín, F Gómez Robina, M Sánchez García, F J Otero Pérez, P Cubero Bros, A Carrillo Gómez, J de Dios Molina Martín, J L Carrasco Perera, M C Averbach, J L Carrasco Perera, E Goenaga Palancares, M T Gallego de Dios, C Fernández Rojo, S Sánchez Iglesias, M I Rubio Merino, N Prieto Mestre, A Pérez Urdaniz, J M Martínez Sánchez, R Gordo Seco, J Franco Muñoz, M Mateos Agut, M L Blanco Lozano, F Martín Herguedas, A Torcal Pena, J Vicente García, A Varona Martínez, O Sanz Sanz Granado, M A Medina Fernández, J M Moran Canseco, P A Megia López, M A Franco Martín, J A Espina Barrio, J Giner Ubago, M Roca Bennassar, J M Olivares Díez, J L Hernandez Fleta, F Porras Fortes, C Arango López, O Medina, D Figuera Alvarez, J M Peña Roca, G Rubio Valladolid, J A Furquet Tavera, J A García-Castrillon Sales, I Batalla Llordes, C Anchuistegui Melgarejo, F Cañas de la Paz, V Vallés Callol, M Bousoño García, J Bobes García, F J Vaz Leal, E Cáceres Corrales, E Sánchez Iglesias, M A Carreiras Gómez, G García Serrano, E G Román Chillarón, F J Samino Aguado, J J Molina Castillo, A González González, J Gallardo Vázquez, M Bolivar Peralvarez, M Rios Diaz, M Ybarzabal Mesa, F J Acosta Artiles, M Ajoy Chao, M Ybarzabal Mesa, P del Rosario Santana, M A García Escudero, M Molla Berenguer, J M Bonete Llacer, J A Juan Berna, J Barragán Ortiz, L Tost Pardell, C Hernández-Alvarez de Sotomayor, M R Cejas Méndez, R Cabrera Garate, B Díaz Múgica, M Caballero González, J Pujol Domingo, C Sáez Navarro, G Selva Vera, M A Cuquerella, J Lonjedo Monzo, P Cervera Boada, M F Martín Pérez, E Carrasco Parrado, J J Yañez Sánchez, J Calvo Fernández.   

Abstract

BACKGROUND: The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is a prospective, observational study of patients with schizophrenia designed to evaluate long-term treatment outcomes in routine clinical practice.
METHODS: Parameters were assessed at baseline and at 3 month intervals for 2 years in patients initiated on risperidone long-acting injection (RLAI) (n=1345) or a new oral antipsychotic (AP) (n=277; 35.7% and 36.5% on risperidone and olanzapine, respectively) in Spain. Hospitalization prior to therapy was assessed by a retrospective chart review.
RESULTS: At 24 months, treatment retention (81.8% for RLAI versus 63.4% for oral APs, p<0.0001) and reduction in Clinical Global Impression Severity scores (-1.14 for RLAI versus -0.94 for APs, p=0.0165) were significantly higher with RLAI. Compared to the pre-switch period, RLAI patients had greater reductions in the number (reduction of 0.37 stays per patient versus 0.2, p<0.05) and days (18.74 versus 13.02, p<0.01) of hospitalizations at 24 months than oral AP patients.
CONCLUSIONS: This 2 year, prospective, observational study showed that, compared to oral antipsychotics, RLAI was associated with better treatment retention, greater improvement in clinical symptoms and functioning, and greater reduction in hospital stays and days in hospital in patients with schizophrenia. Improved treatment adherence, increased efficacy and reduced hospitalization with RLAI offer the opportunity of substantial therapeutic improvement in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19195847     DOI: 10.1016/j.eurpsy.2008.12.002

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  45 in total

Review 1.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.

Authors:  George Bartzokis; Po H Lu; Erika P Raven; Chetan P Amar; Nicole R Detore; Alexander J Couvrette; Jim Mintz; Joseph Ventura; Laurie R Casaus; John S Luo; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2012-07-17       Impact factor: 4.939

3.  Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.

Authors:  Wolfgang Gaebel; Andreas Schreiner; Paul Bergmans; Rosario de Arce; Frédéric Rouillon; Joachim Cordes; Lars Eriksson; Enrico Smeraldi
Journal:  Neuropsychopharmacology       Date:  2010-08-04       Impact factor: 7.853

4.  Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory.

Authors:  George Bartzokis; Po H Lu; Chetan P Amar; Erika P Raven; Nicole R Detore; Lori L Altshuler; Jim Mintz; Joseph Ventura; Laurie R Casaus; John S Luo; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2011-07-20       Impact factor: 4.939

Review 5.  Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.

Authors:  Gregory Kruse; Bruce J O Wong; Mei Sheng Duh; Patrick Lefebvre; Marie-Hélène Lafeuille; John M Fastenau
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

6.  Identifying Predictors of Primary Adherence to Second Generation Long-Acting Injectable Antipsychotics Following Discharge from an Acute Inpatient Psychiatry Unit.

Authors:  Jenna L Gilbert; Leigh Anne Nelson; Carrie R Kriz; Yifei Liu; Courtney A Iuppa; Lauren A Diefenderfer; Ellie S R Elliott; Roger W Sommi
Journal:  Psychopharmacol Bull       Date:  2019-06-20

7.  Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Authors:  Fernanda Rosa; Andreas Schreiner; Pierre Thomas; Tarek Sherif
Journal:  Clin Drug Investig       Date:  2012-04-01       Impact factor: 2.859

8.  Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.

Authors:  Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; Stefan Leucht; Mark Olfson; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

9.  Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.

Authors:  Robin Emsley; Koksal Alptekin; Jean-Michel Azorin; Fernando Cañas; Vincent Dubois; Philip Gorwood; Peter M Haddad; Dieter Naber; José Manuel Olivares; Georgios Papageorgiou; Miguel Roca; Pierre Thomas; Ludger Hargarter; Andreas Schreiner
Journal:  Ther Adv Psychopharmacol       Date:  2015-12

10.  Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

Authors:  Cinzia Niolu; Emanuela Bianciardi; Giorgio Di Lorenzo; Claudia Marchetta; Ylenia Barone; Nicoletta Sterbini; Michele Ribolsi; Giorgio Reggiardo; Alberto Siracusano
Journal:  Ther Adv Psychopharmacol       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.